⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Kodiak Sciences Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Kodiak Sciences Inc.
↗Palo Alto, USA
Kodiak Sciences is a biopharmaceutical company specializing in the development of novel therapeutics for chronic, high-prevalence ophthalmic diseases. The company utilizes its proprietary Antibody Biopolymer Conjugate (ABC) platform to create medicines designed to address unmet needs in retinal vascular diseases, aiming to improve durability and efficacy beyond current standard-of-care anti-VEGF therapies.
The company's late-stage pipeline includes candidates such as tarcocimab tedromer (Zenkuda), KSI-501, and KSI-101. Kodiak is actively advancing these programs through clinical trials, with a focus on indications like wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and macular edema secondary to inflammation (MESI).
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2009
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
STOCK
Exchange:NASDAQ
Ticker:KOD
Market Cap:$2.26B
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Antibody Biopolymer Conjugate (ABC)
Trial Phases:Phase 3: 3
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Lonza (manufacturing partnership for ABC platform)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Victor Perlroth - CEO
Scientific Founders:Stephen A. Charles, Victor Perlroth
LINKS
Website:kodiak.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Kodiak Sciences Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.